Aquestive Therapeutics (AQST) Stock Price, News & Analysis

Company Overview

Aquestive Therapeutics, Inc. is a pharmaceutical company that develops and commercializes medicines using proprietary drug-delivery technologies, including its PharmFilm platform. The company’s oral and buccal films are designed to dissolve in the mouth and may provide alternatives to conventional tablets, capsules, injections, or liquid formulations.

Aquestive’s commercial and partnered products have included treatments for neurological conditions. Its portfolio includes Libervant (diazepam buccal film) for seizure clusters, Exservan (riluzole oral film) for amyotrophic lateral sclerosis, and Sympazan (clonazepam oral film) for certain seizure disorders. The company is also developing Anaphylm, an epinephrine sublingual film intended to address severe allergic reactions, along with other products and product candidates.

The company was formerly known as MonoSol Rx and adopted the Aquestive Therapeutics name in 2018. Headquartered in Warren, New Jersey, Aquestive serves the U.S. market and works with commercial and development partners to support the availability of its products in international markets. Its leadership team is headed by Chief Executive Officer Daniel Barber.

Key Stats

• Today's Range: $4.67 to $4.81
• 50-Day Range: $3.76 to $5.39
• 52-Week Range: $2.93 to $7.55
• Volume: 1.40 million shs
• Average Volume: 1.99 million shs
• Market Capitalization: $586.13 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $8.60
• Consensus Rating: Moderate Buy

Aquestive Therapeutics Stock Analysis - MarketRank™

Aquestive Therapeutics scored higher than 41% of companies evaluated by MarketBeat, and ranked 685th out of 877 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 4.0 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

Aquestive Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.83, and is based on 1 strong buy rating, 4 buy ratings, no hold ratings, and 1 sell rating.

Upside Potential

Aquestive Therapeutics has a consensus price target of $8.60, representing about 84.2% upside from its current price of $4.67.

Amount of Analyst Coverage

Aquestive Therapeutics has only been the subject of 3 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: N/A

Earnings Growth

Earnings for Aquestive Therapeutics are expected to remain at ($0.50) per share in the coming year.

Short Interest

• Score: 0.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

24.58% of the float of Aquestive Therapeutics has been sold short.

Short Interest Ratio / Days to Cover

Aquestive Therapeutics has a short interest ratio ("days to cover") of 13.06, which indicates bearish sentiment.

Change versus previous month

Short interest in Aquestive Therapeutics has recently increased by 5.84%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Aquestive Therapeutics does not currently pay a dividend.

Dividend Growth

Aquestive Therapeutics does not have a long track record of dividend growth.

News and Social Media

• Score: 3.1 / 5
• News Sentiment: 0.91

News Sentiment

Aquestive Therapeutics has a news sentiment score of 0.91. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.70 average news sentiment score of Healthcare companies.

News Coverage This Week

MarketBeat has tracked 2 news articles for Aquestive Therapeutics this week, compared to 7 articles on an average week.

Search Interest

Only 1 people have searched for AQST on MarketBeat in the last 30 days. This is a decrease of -80% compared to the previous 30 days.

MarketBeat Follows

4 people have added Aquestive Therapeutics to their MarketBeat watchlist in the last 30 days. This is an increase of 33% compared to the previous 30 days.

Company Ownership

• Score: 1.3 / 5
• Insider Trading: Selling Shares

Insider Buying vs. Insider Selling

In the past three months, Aquestive Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $166,175.00 in company stock.

Percentage Held by Insiders

6.81% of the stock of Aquestive Therapeutics is held by insiders.

Percentage Held by Institutions

32.45% of the stock of Aquestive Therapeutics is held by institutions.

Company Calendar

• Last Earnings: 8/11/2026
• Today: 10/13/2026
• Next Earnings (Estimated): 11/04/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Pharmaceuticals
• Sub-Industry: Pharmaceuticals
• Current Symbol: NASDAQ:AQST
• CIK: 1398733
• Web: www.aquestive.com
• Phone: (908) 941-1900
• Fax: N/A
• Employees: 147
• Year Founded: 2004

Price Target and Rating

• Average Price Target for Aquestive Therapeutics: $8.60
• High Price Target: $11.00
• Low Price Target: $6.00
• Potential Upside/Downside: +84.2%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.83
• Research Coverage: 6 Analysts

Profitability

• EPS (Trailing Twelve Months): ($0.65)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$83.78 million
• Net Margins: -144.63%
• Pretax Margin: -144.63%
• Return on Equity: N/A
• Return on Assets: -52.40%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 7.19
• Quick Ratio: 6.74

Sales & Book Value

• Annual Sales: $44.54 million
• Price / Sales: 13.16
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: ($0.28) per share
• Price / Book: -16.68

Miscellaneous

• Outstanding Shares: 125,510,000
• Free Float: 116,965,000
• Market Cap: $586.13 million
• Optionable: Optionable
• Beta: 1.49